Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: Results of the GENUINE Phase 3 study By admin / 06/16/2017
Long-term follow-up of the PI3k delta inhibitor TGR-1202 demonstrates a differentiated safety profile and high response rates in CLL: Integrated-analysis of TGR-1202 monotherapy and combined with ublituximab. By admin / 06/01/2016
